Skip to Main Content

Author Details

Hong Fang
National Center for Toxicological Research (NCTR)
2000
115
46
Timothy Clark (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37061083Artificial intelligence and real-world data for drug and food safety - A regulatory science perspective.Regul Toxicol Pharmacol2023
37061083Artificial intelligence and real-world data for drug and food safety - A regulatory science perspective.Regul Toxicol Pharmacol2023
34789871Reporting guidelines for human microbiome research: the STORMS checklist.Nat Med2021
33846644Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology.Nat Biotechnol2021
34789871Reporting guidelines for human microbiome research: the STORMS checklist.Nat Med2021
33846644Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology.Nat Biotechnol2021
33235392FDALabel for drug repurposing studies and beyond.Nat Biotechnol2020
32087354Towards the development of an omics data analysis framework.Regul Toxicol Pharmacol2020
32032705Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine.Drug Discov Today2020
33235392FDALabel for drug repurposing studies and beyond.Nat Biotechnol2020
32032705Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine.Drug Discov Today2020
32087354Towards the development of an omics data analysis framework.Regul Toxicol Pharmacol2020
30871458Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA.BMC Bioinformatics2019
31092200Correction to: Similarities and differences between variants called with human reference genome HG19 or HG38.BMC Bioinformatics2019
30871458Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA.BMC Bioinformatics2019
31092200Correction to: Similarities and differences between variants called with human reference genome HG19 or HG38.BMC Bioinformatics2019
28931315The Liver Toxicity Knowledge Base (LKTB) and drug-induced liver injury (DILI) classification for assessment of human liver injury.Expert Rev Gastroenterol Hepatol2018
28931315The Liver Toxicity Knowledge Base (LKTB) and drug-induced liver injury (DILI) classification for assessment of human liver injury.Expert Rev Gastroenterol Hepatol2018
29067470Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans.Arch Toxicol2018
29067470Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans.Arch Toxicol2018
28073113In vitro to in vivo extrapolation for drug-induced liver injury using a pair ranking method.ALTEX2017
28350954Integrating Drug's Mode of Action into Quantitative Structure-Activity Relationships for Improved Prediction of Drug-Induced Liver Injury.J Chem Inf Model2017
28849567ArrayTrack: An FDA and Public Genomic Tool.Methods Mol Biol2017
28073113In vitro to in vivo extrapolation for drug-induced liver injury using a pair ranking method.ALTEX2017
28350954Integrating Drug's Mode of Action into Quantitative Structure-Activity Relationships for Improved Prediction of Drug-Induced Liver Injury.J Chem Inf Model2017
28849567ArrayTrack: An FDA and Public Genomic Tool.Methods Mol Biol2017
27461952Potential Reuse of Oncology Drugs in the Treatment of Rare Diseases.Trends Pharmacol Sci2016
27319291FDA drug labeling: rich resources to facilitate precision medicine, drug safety, and regulatory science.Drug Discov Today2016
27461952Potential Reuse of Oncology Drugs in the Treatment of Rare Diseases.Trends Pharmacol Sci2016
27319291FDA drug labeling: rich resources to facilitate precision medicine, drug safety, and regulatory science.Drug Discov Today2016
25349334Human sex hormone-binding globulin binding affinities of 125 structurally diverse chemicals and comparison with their binding to androgen receptor, estrogen receptor, and α-fetoprotein.Toxicol Sci2015
25349334Human sex hormone-binding globulin binding affinities of 125 structurally diverse chemicals and comparison with their binding to androgen receptor, estrogen receptor, and α-fetoprotein.Toxicol Sci2015
26506944Molecular regulation of miRNAs and potential biomarkers in the progression of hepatic steatosis to NASH.Biomark Med2015
26501477NETBAGs: a network-based clustering approach with gene signatures for cancer subtyping analysis.Biomark Med2015
26506944Molecular regulation of miRNAs and potential biomarkers in the progression of hepatic steatosis to NASH.Biomark Med2015
26501477NETBAGs: a network-based clustering approach with gene signatures for cancer subtyping analysis.Biomark Med2015
24448476Exploring the FDA adverse event reporting system to generate hypotheses for monitoring of disease characteristics.Clin Pharmacol Ther2014
25633159An investigation of biomarkers derived from legacy microarray data for their utility in the RNA-seq era.Genome Biol2014
24448476Exploring the FDA adverse event reporting system to generate hypotheses for monitoring of disease characteristics.Clin Pharmacol Ther2014
24521015Toward predictive models for drug-induced liver injury in humans: are we there yet?Biomark Med2014
25103881A phenome-guided drug repositioning through a latent variable model.BMC Bioinformatics2014
24958025A testing strategy to predict risk for drug-induced liver injury in humans using high-content screen assays and the 'rule-of-two' model.Arch Toxicol2014
25150839The concordance between RNA-seq and microarray data depends on chemical treatment and transcript abundance.Nat Biotechnol2014
25633159An investigation of biomarkers derived from legacy microarray data for their utility in the RNA-seq era.Genome Biol2014
25150839The concordance between RNA-seq and microarray data depends on chemical treatment and transcript abundance.Nat Biotechnol2014
25103881A phenome-guided drug repositioning through a latent variable model.BMC Bioinformatics2014
24958025A testing strategy to predict risk for drug-induced liver injury in humans using high-content screen assays and the 'rule-of-two' model.Arch Toxicol2014
24521015Toward predictive models for drug-induced liver injury in humans: are we there yet?Biomark Med2014
22935104In silico drug repositioning: what we need to know.Drug Discov Today2013
22935104In silico drug repositioning: what we need to know.Drug Discov Today2013
  • 1 - 50 of 230

Recommended Authors

Lang Li
College of Medicine, The Ohio State University
Career Start Year 2018
Number of shared co-authors 0
Wail Ba-Alawi
Princess Margaret Cancer Centre, University Health Network, University Ave.
Career Start Year 2013
Number of shared co-authors 1
Zichen Wang
Icahn School of Medicine at Mount Sinai
Career Start Year 2013
Number of shared co-authors 1
Nehme El-Hachem
Centre Hospitalier Universitaire Sainte-Justine Research Centre
Career Start Year 2011
Number of shared co-authors 3
Nicholas P Tatonetti
Columbia Universtiy College of Physicians and Surgeons
Career Start Year 2009
Number of shared co-authors 3
Robert M Flight
University of Kentucky
Career Start Year 2007
Number of shared co-authors 1
Jennifer Clarke
Department of Food Science and Technology, University of Nebraska-Lincoln
Career Start Year 2006
Number of shared co-authors 0
Arnaud Droit
Centre de Recherche du CHU de Quebec-Universite, Universite Laval
Career Start Year 2005
Number of shared co-authors 3
Doheon Lee
Korea Advanced Institute of Science and Technology
Career Start Year 2004
Number of shared co-authors 0
Reuben Thomas
Gladstone Institute of Data Science and Biotechnology, Gladstone Institutes
Career Start Year 2004
Number of shared co-authors 1
Lyle D Burgoon
National Center for Environmental Assessment
Career Start Year 2004
Number of shared co-authors 6
David M Reif
Bioinformatics Research Center, North Carolina State University
Career Start Year 2004
Number of shared co-authors 4
J??rg Rahnenf??hrer
TU Dortmund University
Career Start Year 2002
Number of shared co-authors 1
Assaf Gottlieb
Center for Precision Health, University of Texas Health Science Center at Houston
Career Start Year 2002
Number of shared co-authors 0
Lang Li
Harbin Medical University
Career Start Year 2002
Number of shared co-authors 0
Alison A Motsinger-Reif
National Institute of Environmental Health Sciences
Career Start Year 2002
Number of shared co-authors 3
Mark Reimers
Institute for Quantitative Health Science and Engineering, Michigan State University
Career Start Year 2002
Number of shared co-authors 3
William H Bisson
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2001
Number of shared co-authors 1
George C Tseng
University of Pittsburgh School of Public Health
Career Start Year 2001
Number of shared co-authors 0
Kerby Shedden
University of Michigan ann arbor
Career Start Year 1999
Number of shared co-authors 1
Tero Aittokallio
Institute for Molecular Medicine Finland (FIMM), University of Helsinki
Career Start Year 1999
Number of shared co-authors 3
Yingyao Zhou
Genomics Institute of the Novartis Research Foundation
Career Start Year 1997
Number of shared co-authors 1
Katrina M Waters
Pacific Northwest National Laboratory
Career Start Year 1994
Number of shared co-authors 2
Sudhir Varma
Center for Cancer Research, National Cancer Institute
Career Start Year 1994
Number of shared co-authors 2
Gary Hardiman
Institute for Global Food Security, Queen's University Belfast
Career Start Year 1994
Number of shared co-authors 2
Hans Gmuender
F. Hoffmann-La Roche Ltd
Career Start Year 1993
Number of shared co-authors 4
Atul J Butte
Bakar Computational Health Sciences Institute, University of California san francisco
Career Start Year 1993
Number of shared co-authors 2
Christopher P Austin
St. George's University Medical School
Career Start Year 1990
Number of shared co-authors 5
David M Rocke
University of California davis
Career Start Year 1983
Number of shared co-authors 0
Russ B Altman
Stanford University
Career Start Year 1982
Number of shared co-authors 6

Collaborators

Weida Tong
National Center for Toxicological Research
Co-authored papers 105
Ming Shi
Co-authored papers 54
Roger Perkins
Co-authored papers 52
Huixiao Hong
Co-authored papers 46
Zhichao Liu
Co-authored papers 25
Qian Xie
Co-authored papers 23
Zhenqiang Su
Co-authored papers 23
Stephen C Harris
Co-authored papers 19
Joshua Xu
Co-authored papers 17
Minjun Chen
Co-authored papers 16
James C Fuscoe
Co-authored papers 15
Weigong Ge
Co-authored papers 14
Xiaohui Fan
College of Life Sciences, Zhejiang University
Co-authored papers 13
Russell D Wolfinger
SAS Institute
Co-authored papers 10
Baitang Ning
Co-authored papers 10
Federico Goodsaid
Co-authored papers 10
Wenjun Bao
SAS Institute Inc Cary
Co-authored papers 8
Wendell D Jones
Department of Bioinformatics and Clinical Systems
Co-authored papers 7
Tzu-Ming Chu
Co-authored papers 7
Tao Han
Co-authored papers 7
Feng Qian
Co-authored papers 7
Pierre R Bushel
Co-authored papers 6
Liang Zhang
Co-authored papers 6
Shraddha Thakkar
Center for Drug Evaluations and Research (CDER)
Co-authored papers 6
Lei Xu
Co-authored papers 5
Quan-Zhen Li
Co-authored papers 5
Andreas Scherer
Institute for Molecular Medicine Finland (FIMM), University of Helsinki
Co-authored papers 5
John Zhang
Co-authored papers 5
Jing Han
Co-authored papers 5
Tieliu Shi
Co-authored papers 5
Release 1.2